Relief Therapeutics Holding SA (RLF) | Finanzwire

Basculer en Français

8296	Companies
114905	Keywords
55332	Articles
62461	Press releases

Headlines Articles Press releases Relief Therapeutics Holding SA

Home
Companies
Relief Therapeutics Holding SA

BRIEF

published on 10/08/2024 at 07:05, 1 month 13 days ago

Relief Therapeutics Reveals Promising Results in Clinical Trial for Epidermolysis Bullosa

Clinical Trial Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Microbiome Diversity
PRESS RELEASE

published on 10/08/2024 at 07:00, 1 month 13 days ago

Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics reports promising preliminary results of RLF-TD011 clinical trial for epidermolysis bullosa, showing reduced Staphylococcus aureus and improved microbiome diversity

Microbiome Clinical Trial Relief Therapeutics RLF-TD011 Epidermolysis Bullosa
BRIEF

published on 10/04/2024 at 07:05, 1 month 17 days ago

Relief Therapeutics Reports Positive Study Results for Phenylketonuria Treatment

Relief Therapeutics RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride Clinical Study Results
PRESS RELEASE

published on 10/04/2024 at 07:00, 1 month 17 days ago

Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
Relief Therapeutics reports positive results from RLF-OD032 proof-of-concept clinical study for Phenylketonuria, showing bioequivalence with KUVAN(R) in managing PKU. RLF-OD032 aims to offer a patient-friendly, portable solution for PKU treatment

Clinical Study Relief Therapeutics RLF-OD032 Bioéquivalence Phenylketonuria
BRIEF

published on 09/23/2024 at 07:05, 1 month 28 days ago

Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement

FDA Approval Relief Therapeutics Milestone Payment Niemann-Pick Disease SWK Funding
PRESS RELEASE

published on 09/23/2024 at 07:00, 1 month 28 days ago

Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
Relief Therapeutics announced $2 million milestone payment under royalty sales agreement after FDA approval of arimoclomol for Niemann-Pick Disease Type C treatment

FDA Approval Relief Therapeutics Milestone Payment Arimoclomol Royalty Sales Agreement

Accesswire

Published on 11/21/2024 at 13:30, 24 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 24 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 54 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 54 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 54 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 38 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 18 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 38 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 47 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 53 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 56 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 34 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 9 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 9 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE